Chemocentryx Drug Patent Portfolio
Chemocentryx owns 1 orange book drug protected by 4 US patents Given below is the list of Chemocentryx's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11603356 | Amorphous form of a complement component C5a receptor | 27 Nov, 2039 | Active |
| US11951214 | Capsule formulations | 27 Nov, 2039 | Active |
| US8906938 | C5aR antagonists | 06 Jan, 2034 | Active |
| US8445515 | C5aR antagonists | 03 Feb, 2031 | Active |
Latest Legal Activities on Chemocentryx's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Chemocentryx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 05 Aug, 2025 | US11603356 |
| Recordation of Patent eCertificate of Correction | 05 Aug, 2025 | US11603356 |
| Email Notification | 05 Aug, 2025 | US11603356 |
| Mail Patent eCofC Notification | 05 Aug, 2025 | US11603356 |
| Post Issue Communication - Certificate of Correction | 16 Jul, 2025 | US11603356 |
| Mail Pub Notice re 312 amendment | 07 Jul, 2025 | US11603356 |
| Email Notification | 07 Jul, 2025 | US11603356 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 03 Jul, 2025 | US11603356 |
| Post Issue Communication - Certificate of Correction Denied | 03 Jul, 2025 | US11603356 |
| Notice of Final Determination -Eligible | 03 Apr, 2025 | US8906938 |
| Notice of Final Determination -Eligible | 03 Apr, 2025 | US8445515 |
| FDA Final Eligibility Letter | 18 Dec, 2024 | US8906938 |
| FDA Final Eligibility Letter | 18 Dec, 2024 | US8445515 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Oct, 2024 | US8445515 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 16 Apr, 2024 | US11951214 |
Chemocentryx's Family Patents
Chemocentryx Drug List
Given below is the complete list of Chemocentryx's drugs and the patents protecting them.
1. Tavneos
Tavneos is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11603356 | Amorphous form of a complement component C5a receptor |
27 Nov, 2039
(13 years from now)
| Active |
| US11951214 | Capsule formulations |
27 Nov, 2039
(13 years from now)
| Active |
| US8906938 | C5aR antagonists |
06 Jan, 2034
(7 years from now)
| Active |
| US8445515 | C5aR antagonists |
03 Feb, 2031
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tavneos's drug page